How much funding has GlycanAge raised?

GlycanAge has raised $7.4M in total funding, most recently a venture unknown round.

Who are GlycanAge's investors?

GlycanAge's investors include Fifth Quarter Ventures, Guinness Ventures.

Where is GlycanAge headquartered?

GlycanAge is headquartered in Newcastle upon Tyne, United Kingdom.

What industry is GlycanAge in?

GlycanAge operates in Biotech, Healthcare.

GlycanAge

The Ultimate Measure of Inflammaging

Newcastle upon Tyne, United Kingdom · Founded 2020 · $7.4M raised

Biotech

Healthcare

Headquarters: Newcastle upon Tyne
Employees: 11–50
Founded: 2020
Business Model: B2C

Website: glycanage.com
Total Funding: $7.4M
Last Round: $7.4M Venture RoundDec 2025
Rounds: 1

About

GlycanAge is a UK-based biotech company that uses glycan biomarkers to measure biological aging and chronic inflammation. Its test analyzes IgG glycans—the immune system's molecular record—to provide the most sensitive signal of inflammaging, enabling early detection of health risks years before clinical disease appears. Founded in 2020 by Professor Gordan Lauc (CSO) and Nikolina Lauc (CEO), the science is backed by over 30 years of research and 350+ peer-reviewed publications. GlycanAge serves individuals, healthcare providers, and researchers, offering at-home testing kits and clinical integrations. The company is headquartered in Newcastle upon Tyne, UK.

Summary

GlycanAge is a Biotech company based in Newcastle upon Tyne, United Kingdom, founded in 2020. It has raised $7.4M in total across 1 round, most recently a $7.4M Venture Round round in Dec 2025. Investors include Fifth Quarter Ventures and Guinness Ventures.